← Human Trials & Peer-Reviewed Studies
Effects of Recombinant Human Growth Hormone in Children with Crohn's Disease on the Muscle-Bone Unit: A Preliminary Study.
Plain-language guide to PMID 30149380 (2018): pilot clinical trial of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 8 children, muscle disease (myopathy).
Key Facts
- PMID
- 30149380
- Journal
- Hormone research in paediatrics
- Year
- 2018
- Study type
- Clinical Trial
- Authors
- Altowati MA et al. (6 authors)
- DOI
- 10.1159/000492398
What This Study Did, in Plain Language
What Was Tested
Researchers studied Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in the context of muscle disease (myopathy) in this clinical trial publication.
There is limited information on the impact of recombinant human growth hormone (rhGH) on the muscle-bone unit in children with Crohn's disease (CD).
In this pilot study, the researchers report on the effects of rhGH on bone formation, dual-energy X-ray absorptiometry (DXA) total body (TB) bone mineral density adjusted for height and lumbar spine (LS) bone mineral apparent density (BMAD), and body composition.
Who Took Part
The study group was 8 children.
The age groups tagged for this paper are children and teenagers, both men and women.
How the Study Was Run
In design terms this was a pilot study.
It is described as a pilot, a small early test of whether a larger Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study would be practical.
Serum procollagen type 1 N-terminal propeptide (P1NP) was measured at baseline and at 6 months.
DXA was performed every 6 months.
What Was Measured
The subject headings attached to it are Body Composition, Body Height, Bone Density, Bone and Bones, Crohn Disease, Growth Disorders and Human Growth Hormone.
The authors tagged it with the keywords Bone mineral density, Dual-energy X-ray absorptiometry, Inflammation and Procollagen type 1 N-terminal propeptide.
What This Means in Plain Language
The paper is a pilot study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 8 children in people with muscle disease (myopathy).
With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.
Its findings take up roughly 4 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.
The publication is from 2018 (Hormone research in paediatrics), a journal based in Switzerland.
More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, Muscle disease (myopathy) research.
Our Notes on the Compound
Exogenous HGH, sermorelin & older GHRPs (why they're passed over): Constant levels suppress the body's own GHRH, raise somatostatin and dull pituitary response.
Related Pages
- Muscle disease (myopathy) research
- Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in the library
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.